[ATNM] Actinium Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.


Price: 0.97 Change: -0 (-0.5%)
Ext. hours: Change: 0 (0%)

chart ATNM

Refresh chart

Strongest Trends Summary For ATNM

ATNM is in the long-term down -92% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Actinium Pharmaceuticals, Inc., a biotechnology company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform. Its products include Bismab-A for acute myeloid leukemia; Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was formerly known as Cactus Ventures, Inc. and changed its name to Actinium Pharmaceuticals, Inc. in April 2013. Actinium Pharmaceuticals, Inc. was founded in 2000 and is based in New York, New York.

Fundamental Ratios
Shares Outstanding EPS-0.54 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.07
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-55.16% ROE-67.28% ROI
Current Ratio5.52 Quick Ratio Long Term Debt/Equity Debt Ratio0.22
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities18.39 M Cash From Investing Activities Cash From Operating Activities-5.81 M Gross Profit
Net Profit-3.07 M Operating Profit-7.87 M Total Assets20.06 M Total Current Assets19.92 M
Total Current Liabilities3.61 M Total Debt190 K Total Liabilities3.61 M Total Revenue
Technical Data
High 52 week1.06 Low 52 week0.35 Last close0.65 Last change1.56%
RSI59.79 Average true range0.04 Beta0.95 Volume288.91 K
Simple moving average 20 days3.74% Simple moving average 50 days-2.11% Simple moving average 200 days8.43%
Performance Data
Performance Week1.56% Performance Month3.75% Performance Quart65.86% Performance Half-13.25%
Performance Year-30.11% Performance Year-to-date-2.05% Volatility daily2.99% Volatility weekly6.68%
Volatility monthly13.69% Volatility yearly47.42% Relative Volume353.16% Average Volume1.75 M
New High New Low


2019-03-20 08:00:00 | Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting

2019-03-19 17:05:00 | Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs

2019-03-19 17:00:00 | Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights

2019-03-15 17:05:00 | Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings

2019-03-15 08:00:00 | Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference

2019-03-07 12:15:09 | What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s NYSEMKT:ATNM?

2019-02-25 14:20:00 | 4 Healthcare Stocks Looking To Kick Off A Strong Week

2019-02-25 08:00:00 | Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial

2019-02-21 08:00:00 | Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy

2019-02-15 07:40:00 | Consolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes S.A, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce — Fundamental Analysis, Key Performance Indications

2019-02-12 08:00:00 | Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting

2019-02-06 08:00:00 | Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program

2019-02-05 08:00:00 | Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax

2019-02-04 08:00:00 | Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin

2019-01-29 08:00:00 | Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th

2019-01-25 08:00:00 | Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference

2019-01-23 08:00:00 | Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain

2019-01-17 08:00:00 | Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated

2019-01-16 08:00:00 | Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies

2019-01-03 08:00:00 | Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco

2018-12-21 14:08:55 | How Does Investing In Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM Impact The Volatility Of Your Portfolio?

2018-12-04 08:00:00 | Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting

2018-12-03 08:00:00 | Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate

2018-11-19 08:00:00 | Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference

2018-11-05 08:00:00 | Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference

2018-11-01 09:01:00 | Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data

2018-10-30 17:05:00 | Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax

2018-10-26 08:00:00 | Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

2018-10-24 08:00:00 | Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference

2018-10-22 09:30:01 | Has Actinium Pharmaceuticals ATNM Outpaced Other Medical Stocks This Year?

2018-10-22 08:43:12 | Do Options Traders Know Something About Actinium ATNM Stock We Don't?

2018-10-22 08:04:00 | Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

2018-10-19 08:10:00 | Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals — Discovering Underlying Factors of Influence

2018-10-16 07:12:11 | Top Ranked Momentum Stocks to Buy for October 16th

2018-10-15 07:21:11 | Top Ranked Momentum Stocks to Buy for October 15th

2018-10-01 08:00:00 | Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers

2018-09-26 08:00:00 | Actinium Pharmaceuticals to Host Webinar Today Introducing Next Generation Targeted Lymphodepletion Technology for CAR-T

2018-09-20 08:00:00 | Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease

2018-09-18 09:34:44 | Should You Worry About The Actinium Pharmaceuticals Inc’s NYSEMKT:ATNM Shareholder Register?

2018-09-18 08:00:00 | Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space

2018-09-06 08:00:00 | Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations

2018-09-05 18:37:00 | Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions

2018-08-14 16:05:00 | Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting

2018-07-17 17:30:11 | Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning

2018-07-09 16:15:00 | Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients

2018-07-02 07:05:00 | Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

2018-06-28 08:00:00 | Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients

2018-06-26 08:00:00 | Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial

2018-06-25 16:15:00 | Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting

2018-06-20 08:05:23 | Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18